Hospital
Mercy Health Partners
Mercy Health Partners was paid $98.26M by Medicaid between Jan 2018 and Dec 2024, across 674 billing codes. Its largest line is 99285, emergency room visit (most serious) — 14% of everything it billed.
33Billing provider infoMERCY HEALTH PARTNERS
MUSKEGON, MI 49444
MUSKEGON, MI 49444
33aNPI1831132133assigned 06/14/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$98.26M
24GClaims3,195,800
24DCodes billed674
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Michigan
Rank by total paid#8 of 86
Median peer was paid$21.55M
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 437,095 | $12.05M | |
| 2019 | 419,722 | $10.92M | |
| 2020 | 402,507 | $11.81M | |
| 2021 | 548,052 | $18.43M | |
| 2022 | 530,195 | $17.21M | |
| 2023 | 499,850 | $16.33M | |
| 2024incomplete | 358,379 | $11.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 48,294 | 43,396 | $14.03M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 226,887 | 188,869 | $13.24M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 56,360 | 51,503 | $10.46M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 8.8% | 70,796 | 65,921 | $8.66M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.3% | 44,130 | 38,280 | $4.23M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.9% | 31,626 | 30,055 | $1.90M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.8% | 24,864 | 24,111 | $1.78M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 12,201 | 11,802 | $1.67M |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 38,608 | 36,609 | $1.40M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.4% | 52,791 | 17,922 | $1.33M |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.3% | 3,853 | 3,830 | $1.26M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.3% | 13,766 | 13,170 | $1.25M |
662 more codes
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 1.3% | 401 | $1.25M |
| G0382 | Level 3 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | 1.0% | 11,957 | $1.03M |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.0% | 2,061 | $994K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 10,775 | $926K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 30,913 | $874K |
| 59025 | Fetal non-stress test | <1% | 9,205 | $826K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 2,055 | $817K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 805 | $801K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,882 | $756K |
| 71045 | Radiologic examination, chest; single view | <1% | 18,734 | $719K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 7,201 | $687K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 21,988 | $638K |
| G0381 | Level 2 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 13,176 | $633K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 216 | $578K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,389 | $575K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 8,813 | $561K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 38,998 | $536K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 38,940 | $534K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 5,484 | $525K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 4,616 | $494K |
| 80061 | Lipid panel | <1% | 29,030 | $435K |
| G0383 | Level 4 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 3,991 | $434K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 6,851 | $431K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,022 | $420K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 4,496 | $416K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 127 | $407K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 7,320 | $407K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 8,555 | $399K |
| 76830 | Ultrasound, transvaginal | <1% | 6,978 | $398K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 33,293 | $385K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 16,019 | $373K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 21,968 | $357K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 18,815 | $350K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 718 | $341K |
| 97161 | <1% | 6,542 | $326K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 5,928 | $319K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,889 | $316K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 775 | $313K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 3,073 | $298K |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 278 | $292K |
| 76801 | <1% | 4,658 | $269K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 4,586 | $265K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,655 | $256K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 39,313 | $245K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 2,014 | $240K |
| 80053 | Comprehensive metabolic panel | <1% | 130,527 | $237K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 24,040 | $232K |
| 97162 | <1% | 5,141 | $228K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 46,142 | $226K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 3,610 | $221K |
| G0378 | Hospital observation service, per hour | <1% | 4,037 | $218K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 3,484 | $217K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 6,730 | $215K |
| 94060 | <1% | 1,749 | $211K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 17,246 | $211K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 3,422 | $210K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 7,253 | $210K |
| 86900 | <1% | 12,924 | $194K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 3,093 | $193K |
| 72141 | <1% | 1,512 | $192K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 4,610 | $177K |
| 87480 | <1% | 23,301 | $175K | |
| 87660 | <1% | 23,280 | $174K | |
| 87510 | <1% | 22,948 | $169K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 128,343 | $165K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 321 | $165K |
| J2357 | Injection, omalizumab, 5 mg | <1% | 188 | $162K |
| 10060 | <1% | 1,686 | $154K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 217 | $149K |
| G0380 | Level 1 hospital emergency department visit provided in a type b emergency department; (the ed must meet at least one of the following requirements: (1) it is licensed by the state in which it is located under applicable state law as an emergency room or emergency department; (2) it is held out to the public (by name, posted signs, advertising, or other means) as a place that provides care for emergency medical conditions on an urgent basis without requiring a previously scheduled appointment; or (3) during the calendar year immediately preceding the calendar year in which a determination under 42 cfr 489.24 is being made, based on a representative sample of patient visits that occurred during that calendar year, it provides at least one-third of all of its outpatient visits for the treatment of emergency medical conditions on an urgent basis without requiring a previously scheduled appointment) | <1% | 3,521 | $145K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 2,767 | $142K |
| 49083 | <1% | 301 | $141K | |
| 90686 | <1% | 10,055 | $138K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 13,584 | $137K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 5,153 | $135K |
| 73221 | <1% | 1,152 | $131K | |
| 93971 | <1% | 2,322 | $123K | |
| 47562 | <1% | 44 | $120K | |
| 76642 | <1% | 3,065 | $119K | |
| 90651 | <1% | 1,600 | $113K | |
| 90677 | <1% | 675 | $113K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,007 | $107K |
| 70491 | <1% | 1,050 | $107K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 896 | $106K |
| Q3014 | Telehealth originating site facility fee | <1% | 5,615 | $102K |
| G0475 | Hiv antigen/antibody, combination assay, screening | <1% | 7,214 | $101K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 25,291 | $100K |
| 76536 | <1% | 1,923 | $99K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 4,404 | $98K |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 140 | $97K |
| 36415 | Collection of venous blood by venipuncture | <1% | 97,018 | $96K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 6,110 | $96K |
| 97165 | <1% | 2,414 | $93K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,044 | $91K |
| 72110 | <1% | 2,248 | $89K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,617 | $88K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 5,956 | $88K |
| 64400 | <1% | 595 | $85K | |
| 62323 | <1% | 355 | $85K | |
| 70496 | <1% | 996 | $81K | |
| 71271 | <1% | 1,414 | $80K | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 3,154 | $79K |
| 29581 | <1% | 1,133 | $78K | |
| 86003 | <1% | 1,917 | $78K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,473 | $75K |
| 93017 | <1% | 2,126 | $74K | |
| 58301 | <1% | 543 | $73K | |
| 71250 | <1% | 1,471 | $73K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 6,896 | $72K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 52,186 | $70K |
| 80074 | <1% | 3,790 | $69K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 31,150 | $68K |
| 64615 | <1% | 514 | $67K | |
| 72100 | <1% | 4,816 | $67K | |
| 72158 | <1% | 402 | $66K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 4,704 | $65K |
| 95806 | <1% | 845 | $64K | |
| 70486 | <1% | 2,297 | $63K | |
| 82728 | <1% | 11,144 | $63K | |
| 93798 | <1% | 928 | $61K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 11,822 | $59K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 361 | $57K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 125 | $57K |
| 87653 | <1% | 4,427 | $55K | |
| 76775 | <1% | 1,759 | $54K | |
| 82607 | <1% | 8,627 | $54K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,250 | $53K |
| 0002A | <1% | 1,593 | $52K | |
| 64405 | <1% | 389 | $52K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 137 | $51K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 348 | $51K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 4,956 | $50K |
| 95811 | <1% | 106 | $49K | |
| 93976 | <1% | 914 | $48K | |
| 73630 | <1% | 5,948 | $48K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 3,160 | $48K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 3,186 | $48K |
| 74018 | <1% | 3,321 | $48K | |
| 76818 | <1% | 812 | $48K | |
| 74019 | <1% | 2,264 | $46K | |
| 72050 | <1% | 1,091 | $46K | |
| 99406 | <1% | 3,479 | $46K | |
| 64493 | <1% | 110 | $45K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 175 | $45K |
| 73030 | <1% | 4,572 | $45K | |
| 88342 | <1% | 3,019 | $44K | |
| 99385 | <1% | 664 | $42K | |
| 73562 | <1% | 4,253 | $42K | |
| 0001A | <1% | 1,690 | $42K | |
| 94726 | <1% | 1,799 | $41K | |
| 73610 | <1% | 4,586 | $40K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 19,149 | $40K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 1,612 | $39K |
| 84702 | <1% | 9,063 | $39K | |
| 85027 | <1% | 24,226 | $39K | |
| 93970 | <1% | 334 | $37K | |
| 87070 | <1% | 12,367 | $36K | |
| 51700 | <1% | 270 | $35K | |
| 72072 | <1% | 1,493 | $34K | |
| 73130 | <1% | 5,165 | $34K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 148 | $33K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 1,413 | $32K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 5,051 | $32K |
| 86780 | <1% | 3,808 | $30K | |
| 86803 | <1% | 4,935 | $30K | |
| 77080 | <1% | 541 | $30K | |
| 93225 | <1% | 715 | $30K | |
| 86235 | <1% | 647 | $29K | |
| 76770 | <1% | 513 | $29K | |
| 64483 | <1% | 81 | $28K | |
| 90670 | <1% | 1,821 | $28K | |
| 91200 | <1% | 708 | $27K | |
| 73110 | <1% | 2,879 | $27K | |
| 84439 | <1% | 8,559 | $27K | |
| 83540 | <1% | 9,159 | $26K | |
| 58558 | <1% | 51 | $26K | |
| 73564 | <1% | 1,240 | $26K | |
| 20553 | <1% | 228 | $25K | |
| 73140 | <1% | 2,018 | $25K | |
| 87522 | Neg quan hep c or qual rna | <1% | 1,481 | $25K |
| 87077 | <1% | 10,594 | $25K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,124 | $24K |
| 87186 | <1% | 9,877 | $24K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 91 | $24K |
| 87536 | <1% | 552 | $23K | |
| 58661 | <1% | 12 | $23K | |
| 77065 | Tomosynthesis, mammo | <1% | 570 | $23K |
| 58100 | <1% | 268 | $23K | |
| 73700 | <1% | 424 | $23K | |
| 20610 | <1% | 201 | $22K | |
| 17110 | <1% | 442 | $22K | |
| 84466 | <1% | 3,846 | $22K | |
| 73502 | <1% | 2,069 | $21K | |
| 86480 | <1% | 676 | $21K | |
| 87340 | <1% | 5,616 | $21K | |
| 83970 | <1% | 1,080 | $21K | |
| 58300 | <1% | 1,200 | $20K | |
| 83880 | <1% | 10,602 | $19K | |
| 72082 | <1% | 360 | $19K | |
| 87641 | <1% | 1,879 | $19K | |
| 90620 | <1% | 329 | $19K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,651 | $19K |
| 62321 | <1% | 76 | $19K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,821 | $18K |
| 82746 | <1% | 2,882 | $18K | |
| 85610 | <1% | 35,521 | $18K | |
| 91320 | <1% | 159 | $17K | |
| 86850 | <1% | 12,278 | $17K | |
| 76870 | <1% | 965 | $17K | |
| 86762 | <1% | 4,047 | $17K | |
| 57454 | <1% | 114 | $17K | |
| 92523 | <1% | 152 | $17K | |
| 83655 | <1% | 2,761 | $16K | |
| 87081 | <1% | 11,940 | $15K | |
| 83735 | <1% | 35,507 | $15K | |
| 72040 | <1% | 1,483 | $15K | |
| 82043 | <1% | 5,497 | $15K | |
| 83550 | <1% | 3,875 | $15K | |
| 82570 | <1% | 7,319 | $14K | |
| 84403 | <1% | 1,247 | $14K | |
| 87088 | <1% | 7,183 | $13K | |
| 0124A | <1% | 484 | $13K | |
| 86140 | <1% | 12,104 | $13K | |
| 93246 | <1% | 815 | $13K | |
| 82105 | <1% | 1,824 | $13K | |
| L4350 | Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf | <1% | 306 | $13K |
| 81001 | <1% | 47,942 | $13K | |
| 90734 | <1% | 1,078 | $12K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,255 | $12K |
| 83516 | <1% | 1,988 | $12K | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 207 | $12K |
| 87899 | <1% | 1,242 | $12K | |
| 88304 | <1% | 2,593 | $12K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 152 | $12K |
| 84481 | <1% | 2,099 | $12K | |
| 84146 | <1% | 1,302 | $12K | |
| 88307 | <1% | 609 | $12K | |
| 82784 | <1% | 2,152 | $11K | |
| 83020 | <1% | 2,571 | $11K | |
| 87640 | <1% | 1,029 | $11K | |
| 80055 | <1% | 434 | $11K | |
| 82950 | <1% | 4,015 | $11K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 39 | $11K |
| 96415 | <1% | 294 | $10K | |
| 81025 | <1% | 5,279 | $10K | |
| 86039 | <1% | 2,096 | $10K | |
| 90746 | <1% | 150 | $10K | |
| 73080 | <1% | 1,507 | $10K | |
| 97116 | <1% | 1,659 | $10K | |
| 87147 | <1% | 7,084 | $10K | |
| 0054A | <1% | 288 | $9K | |
| 0004A | <1% | 284 | $9K | |
| 86592 | <1% | 4,127 | $9K | |
| 88341 | <1% | 320 | $9K | |
| 86769 | <1% | 444 | $9K | |
| 83001 | <1% | 987 | $9K | |
| 72170 | <1% | 1,324 | $9K | |
| 86364 | <1% | 1,045 | $9K | |
| 78830 | <1% | 12 | $9K | |
| 84425 | <1% | 820 | $9K | |
| 90732 | <1% | 130 | $8K | |
| 99496 | <1% | 141 | $8K | |
| 99495 | <1% | 141 | $8K | |
| 73590 | <1% | 1,720 | $8K | |
| 76882 | <1% | 153 | $7K | |
| 78451 | <1% | 14 | $7K | |
| 84703 | <1% | 35,167 | $7K | |
| 80076 | <1% | 2,770 | $7K | |
| G0101 | Cervical or vaginal cancer screening; pelvic and clinical breast examination | <1% | 172 | $7K |
| 97035 | <1% | 1,311 | $7K | |
| 96127 | <1% | 1,766 | $7K | |
| 86225 | <1% | 1,003 | $7K | |
| 71101 | <1% | 472 | $6K | |
| 90656 | <1% | 461 | $6K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 411 | $6K |
| 85730 | <1% | 19,702 | $6K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,172 | $6K |
| 97166 | <1% | 183 | $6K | |
| 70498 | <1% | 909 | $6K | |
| 90480 | <1% | 171 | $6K | |
| 86038 | <1% | 1,087 | $6K | |
| 85652 | <1% | 7,905 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 8,957 | $6K |
| 11982 | <1% | 53 | $6K | |
| 86376 | <1% | 810 | $6K | |
| 82565 | <1% | 2,435 | $6K | |
| 86258 | <1% | 500 | $6K | |
| 99000 | <1% | 449 | $5K | |
| 0012A | <1% | 183 | $5K | |
| 93296 | <1% | 353 | $5K | |
| 43450 | <1% | 51 | $5K | |
| 84156 | <1% | 4,661 | $5K | |
| 87529 | <1% | 414 | $5K | |
| 73090 | <1% | 1,247 | $5K | |
| 72131 | <1% | 101 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 10,603 | $5K |
| 86901 | <1% | 12,886 | $5K | |
| 84590 | <1% | 831 | $5K | |
| 84550 | <1% | 3,736 | $5K | |
| 86706 | <1% | 1,065 | $5K | |
| 82670 | <1% | 322 | $5K | |
| 82652 | <1% | 318 | $5K | |
| 86200 | <1% | 755 | $5K | |
| 95819 | <1% | 34 | $5K | |
| 82785 | <1% | 561 | $5K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 42 | $4K |
| 93226 | <1% | 699 | $4K | |
| 86593 | <1% | 1,707 | $4K | |
| 99383 | <1% | 66 | $4K | |
| 83690 | <1% | 32,140 | $4K | |
| 11981 | <1% | 123 | $4K | |
| 94010 | <1% | 287 | $4K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 139 | $4K |
| 36430 | <1% | 21 | $4K | |
| 86696 | <1% | 442 | $4K | |
| 81003 | <1% | 23,069 | $4K | |
| 84100 | <1% | 12,747 | $4K | |
| 97163 | <1% | 110 | $4K | |
| 84630 | <1% | 770 | $4K | |
| 87625 | <1% | 244 | $4K | |
| 84207 | <1% | 282 | $4K | |
| 82180 | <1% | 867 | $4K | |
| 0011A | <1% | 206 | $4K | |
| 84134 | <1% | 445 | $3K | |
| 82248 | <1% | 2,285 | $3K | |
| 88300 | <1% | 496 | $3K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 2,174 | $3K |
| 93880 | <1% | 38 | $3K | |
| 84520 | <1% | 1,780 | $3K | |
| 90474 | <1% | 676 | $3K | |
| 82951 | <1% | 436 | $3K | |
| 97012 | <1% | 537 | $3K | |
| 82550 | <1% | 5,730 | $3K | |
| 78227 | <1% | 12 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 266 | $3K |
| 83615 | <1% | 3,854 | $3K | |
| 87045 | <1% | 803 | $3K | |
| 87205 | <1% | 3,943 | $3K | |
| 86695 | <1% | 442 | $3K | |
| 95816 | <1% | 24 | $3K | |
| 81002 | <1% | 7,087 | $3K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 34 | $3K |
| 80164 | <1% | 789 | $3K | |
| 85048 | <1% | 1,854 | $3K | |
| 78264 | <1% | 12 | $2K | |
| 73560 | <1% | 239 | $2K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 13 | $2K |
| 72197 | <1% | 12 | $2K | |
| 85007 | <1% | 3,943 | $2K | |
| 83002 | <1% | 255 | $2K | |
| 97802 | <1% | 67 | $2K | |
| 72156 | <1% | 12 | $2K | |
| 74174 | <1% | 12 | $2K | |
| 86360 | <1% | 90 | $2K | |
| 82962 | <1% | 2,126 | $2K | |
| 86141 | <1% | 436 | $2K | |
| 80081 | <1% | 93 | $2K | |
| 86430 | <1% | 769 | $2K | |
| 29515 | <1% | 26 | $2K | |
| 73552 | <1% | 785 | $2K | |
| 86431 | <1% | 779 | $2K | |
| 99386 | <1% | 29 | $2K | |
| 93922 | <1% | 61 | $2K | |
| 93975 | <1% | 14 | $2K | |
| 77336 | <1% | 24 | $2K | |
| 87328 | <1% | 290 | $2K | |
| 90694 | <1% | 164 | $2K | |
| 74183 | <1% | 13 | $2K | |
| 82247 | <1% | 648 | $2K | |
| 85379 | <1% | 9,150 | $2K | |
| 87329 | <1% | 311 | $2K | |
| 87040 | <1% | 6,873 | $2K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,052 | $2K |
| 90744 | <1% | 729 | $2K | |
| 95910 | <1% | 12 | $2K | |
| 99381 | <1% | 25 | $2K | |
| 84153 | <1% | 163 | $1K | |
| 82805 | <1% | 3,508 | $1K | |
| 87210 | <1% | 8,758 | $1K | |
| 87807 | <1% | 2,037 | $1K | |
| 86800 | <1% | 167 | $1K | |
| 82140 | <1% | 1,440 | $1K | |
| 86160 | <1% | 117 | $1K | |
| 83993 | <1% | 120 | $1K | |
| 83013 | <1% | 39 | $1K | |
| 89051 | <1% | 695 | $1K | |
| 90716 | <1% | 134 | $1K | |
| 83605 | <1% | 17,460 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 1,009 | $1K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 65 | $1K |
| 86147 | <1% | 39 | $1K | |
| 84484 | <1% | 31,068 | $998.79 | |
| 84165 | <1% | 195 | $947.20 | |
| 85018 | <1% | 1,132 | $943.47 | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 78 | $936.55 |
| 86308 | <1% | 1,532 | $925.78 | |
| 86694 | <1% | 146 | $917.73 | |
| 85045 | <1% | 677 | $883.87 | |
| 73660 | <1% | 41 | $883.22 | |
| 87015 | <1% | 363 | $862.18 | |
| 90837 | Psychotherapy session, about an hour | <1% | 16 | $847.37 |
| 82947 | <1% | 387 | $817.57 | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 32 | $763.44 |
| 73060 | <1% | 179 | $755.15 | |
| 96367 | <1% | 32 | $749.43 | |
| 83014 | <1% | 249 | $740.02 | |
| 83525 | <1% | 150 | $737.09 | |
| 80305 | <1% | 199 | $732.10 | |
| 84450 | <1% | 288 | $722.31 | |
| 87046 | <1% | 239 | $715.74 | |
| 70480 | <1% | 12 | $662.19 | |
| 93271 | <1% | 12 | $661.26 | |
| 69209 | <1% | 457 | $658.48 | |
| 86677 | <1% | 303 | $655.22 | |
| 93298 | <1% | 55 | $653.57 | |
| 84446 | <1% | 95 | $651.16 | |
| 82952 | <1% | 289 | $646.48 | |
| 0031A | <1% | 37 | $632.39 | |
| 84144 | <1% | 70 | $628.72 | |
| 93289 | <1% | 79 | $628.00 | |
| 84460 | <1% | 244 | $625.90 | |
| 82150 | <1% | 375 | $621.79 | |
| 31500 | <1% | 32 | $618.71 | |
| 88142 | <1% | 72 | $549.07 | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 13 | $525.88 |
| 84681 | <1% | 75 | $521.71 | |
| 0051A | <1% | 14 | $489.39 | |
| 0071A | <1% | 26 | $457.23 | |
| 94618 | <1% | 28 | $456.12 | |
| 76820 | <1% | 409 | $454.98 | |
| 12001 | <1% | 2,410 | $450.83 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 40,793 | $446.82 |
| 29125 | <1% | 222 | $443.41 | |
| 72220 | <1% | 24 | $432.80 | |
| 83520 | <1% | 2,060 | $429.44 | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 20 | $428.07 |
| 0003A | <1% | 19 | $424.65 | |
| 90674 | <1% | 15 | $420.96 | |
| 86708 | <1% | 63 | $418.65 | |
| 12011 | <1% | 1,188 | $413.18 | |
| 82533 | <1% | 55 | $404.74 | |
| 73522 | <1% | 13 | $401.10 | |
| 82677 | <1% | 28 | $396.79 | |
| 82945 | <1% | 283 | $396.42 | |
| 12002 | <1% | 983 | $385.23 | |
| 90662 | <1% | 108 | $377.91 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 768 | $358.23 |
| A9270 | Non-covered item or service | <1% | 3,557 | $353.00 |
| 92610 | <1% | 12 | $347.27 | |
| 98960 | <1% | 16 | $342.08 | |
| 85660 | <1% | 126 | $324.44 | |
| 84445 | <1% | 12 | $319.60 | |
| 87563 | <1% | 31 | $319.43 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 829 | $308.18 |
| 84145 | <1% | 1,667 | $306.71 | |
| 82010 | <1% | 2,635 | $303.55 | |
| 90653 | <1% | 19 | $288.41 | |
| 98926 | <1% | 1,840 | $282.28 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 1,624 | $273.60 |
| 88112 | <1% | 28 | $258.67 | |
| 87521 | Neg quan hep c or qual rna | <1% | 12 | $256.16 |
| 82731 | <1% | 54 | $255.42 | |
| 86336 | <1% | 28 | $254.51 | |
| 94729 | <1% | 1,885 | $252.00 | |
| 86337 | <1% | 27 | $245.26 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 7,333 | $239.55 |
| 88312 | <1% | 189 | $224.38 | |
| 84132 | <1% | 429 | $217.65 | |
| 82040 | <1% | 189 | $213.96 | |
| 86618 | <1% | 25 | $205.77 | |
| 80178 | <1% | 86 | $201.20 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 36,187 | $200.21 |
| 82525 | <1% | 26 | $177.17 | |
| 84436 | <1% | 99 | $176.05 | |
| 86036 | <1% | 14 | $146.65 | |
| 86920 | <1% | 27 | $146.59 | |
| 73000 | <1% | 15 | $145.44 | |
| 82627 | <1% | 15 | $135.86 | |
| 98927 | <1% | 2,265 | $135.53 | |
| 98928 | <1% | 1,150 | $134.47 | |
| 51798 | <1% | 240 | $134.08 | |
| 82553 | <1% | 2,276 | $126.90 | |
| 86231 | <1% | 25 | $125.55 | |
| Q0114 | Fern test | <1% | 25 | $119.00 |
| 73620 | <1% | 14 | $118.34 | |
| 80197 | <1% | 22 | $113.08 | |
| 87324 | <1% | 36 | $110.19 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 38,636 | $109.23 |
| 88311 | <1% | 152 | $100.68 | |
| 97018 | <1% | 41 | $96.66 | |
| G0010 | Administration of hepatitis b vaccine | <1% | 14 | $91.98 |
| 90473 | <1% | 50 | $87.84 | |
| 86787 | <1% | 14 | $87.12 | |
| 97113 | <1% | 108 | $86.62 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 22,139 | $85.27 |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 2,057 | $82.32 |
| 98925 | <1% | 198 | $81.07 | |
| 70360 | <1% | 38 | $76.39 | |
| 76937 | <1% | 1,308 | $76.30 | |
| 86015 | <1% | 14 | $71.79 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 12,862 | $69.95 |
| 70030 | <1% | 12 | $67.98 | |
| 80069 | <1% | 19 | $62.79 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,833 | $62.62 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 13,127 | $61.56 |
| 90715 | <1% | 7,913 | $61.07 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 14,357 | $58.77 |
| 87106 | <1% | 15 | $57.79 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 8,322 | $56.60 |
| 87101 | <1% | 30 | $54.53 | |
| 87075 | <1% | 62 | $53.71 | |
| 85014 | <1% | 58 | $43.47 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 8,934 | $41.59 |
| 87220 | <1% | 31 | $36.71 | |
| 88302 | <1% | 41 | $32.38 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,242 | $32.25 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 585 | $31.22 |
| 96376 | <1% | 6,827 | $24.80 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,299 | $23.82 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 3,089 | $23.01 |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 546 | $22.36 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 1,000 | $17.21 |
| 80177 | <1% | 12 | $16.12 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 1,456 | $15.56 |
| 94664 | <1% | 544 | $15.32 | |
| J2704 | Injection, propofol, 10 mg | <1% | 25,485 | $13.58 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 9,224 | $12.76 |
| 85384 | <1% | 13 | $12.10 | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 16 | $8.30 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 15,046 | $8.22 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | <1% | 108 | $7.42 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 21,452 | $7.08 |
| 82800 | <1% | 162 | $6.14 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 2,365 | $5.75 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,989 | $5.47 |
| C1751 | Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) | <1% | 2,756 | $4.49 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 373 | $3.55 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 182 | $3.16 |
| 82272 | <1% | 24 | $2.15 | |
| J1836 | Injection, metronidazole, 10 mg | <1% | 52 | $2.03 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,603 | $0.54 |
| 36416 | <1% | 287 | $0.04 | |
| J3490 | Unclassified drugs | <1% | 5,064 | $0.01 |
| 90710 | 0% | 222 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 769 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 3,098 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 2,639 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 3,298 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 2,456 | $0.00 |
| 90700 | 0% | 314 | $0.00 | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 774 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 861 | $0.00 |
| 90648 | 0% | 474 | $0.00 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 902 | $0.00 |
| 77062 | 0% | 84 | $0.00 | |
| J0295 | Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm | 0% | 59 | $0.00 |
| L3908 | Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf | 0% | 371 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 699 | $0.00 |
| 98929 | 0% | 308 | $0.00 | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 0% | 3,162 | $0.00 |
| 90633 | 0% | 1,246 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 997 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 41 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 2,273 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 339 | $0.00 |
| 36600 | 0% | 141 | $0.00 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 289 | $0.00 |
| 99152 | 0% | 394 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 38 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 508 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 293 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 383 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 613 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 192 | $0.00 |
| A4312 | Insertion tray without drainage bag with indwelling catheter, foley type, two-way, all silicone | 0% | 66 | $0.00 |
| 90681 | 0% | 153 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 141 | $0.00 |
| 90685 | 0% | 94 | $0.00 | |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 93 | $0.00 |
| Q0177 | Hydroxyzine pamoate, 25 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 451 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 312 | $0.00 |
| L1830 | Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf | 0% | 137 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 133 | $0.00 |
| C1729 | Catheter, drainage | 0% | 81 | $0.00 |
| 64495 | 0% | 102 | $0.00 | |
| 76000 | 0% | 29 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 193 | $0.00 |
| 82075 | 0% | 96 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 93 | $0.00 |
| 76942 | 0% | 14 | $0.00 | |
| 90707 | 0% | 136 | $0.00 | |
| 64447 | 0% | 25 | $0.00 | |
| 90461 | 0% | 45 | $0.00 | |
| 77002 | 0% | 12 | $0.00 | |
| 90714 | 0% | 12 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 190 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 13 | $0.00 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 22 | $0.00 |
| 90713 | 0% | 15 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 12 | $0.00 |
| 16020 | 0% | 27 | $0.00 | |
| 94645 | 0% | 15 | $0.00 | |
| 91300 | 0% | 14 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 25 | $0.00 |
| A6219 | Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 12 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 19 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 630 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 2,800 | $0.00 |
| 90698 | 0% | 1,163 | $0.00 | |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 12 | $0.00 |
| C1769 | Guide wire | 0% | 1,664 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 1,286 | $0.00 |
| 90680 | 0% | 878 | $0.00 | |
| A6223 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size more than 16 sq. in., but less than or equal to 48 sq. in., without adhesive border, each dressing | 0% | 134 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,727 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 1,241 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,596 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 1,503 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 4,769 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 111 | $0.00 |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | 0% | 205 | $0.00 |
| A4338 | Indwelling catheter; foley type, two-way latex with coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each | 0% | 420 | $0.00 |
| 83986 | 0% | 44 | $0.00 | |
| 95886 | 0% | 363 | $0.00 | |
| L3927 | Finger orthosis, proximal interphalangeal (pip)/distal interphalangeal (dip), without joint/spring, extension/flexion (e.g., static or ring type), may include soft interface material, prefabricated, off-the-shelf | 0% | 54 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 219 | $0.00 |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | 0% | 164 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 649 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 1,039 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 1,738 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 569 | $0.00 |
| 90723 | 0% | 258 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 1,336 | $0.00 |
| 84270 | 0% | 30 | $0.00 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 192 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 1,789 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 52 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 164 | $0.00 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 70 | $0.00 |
| 90632 | 0% | 311 | $0.00 | |
| A4344 | Indwelling catheter, foley type, two-way, all silicone or polyurethane, each | 0% | 224 | $0.00 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 72 | $0.00 |
| 94760 | 0% | 201 | $0.00 | |
| 64484 | 0% | 66 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 26 | $0.00 |
| G0453 | Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure) | 0% | 13 | $0.00 |
| 64415 | 0% | 38 | $0.00 | |
| 94644 | 0% | 83 | $0.00 | |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 137 | $0.00 |
| 64494 | 0% | 104 | $0.00 | |
| A4351 | Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, or silicone elastomer, etc.), each | 0% | 74 | $0.00 |
| 95870 | 0% | 13 | $0.00 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 76 | $0.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 154 | $0.00 |
| 74420 | 0% | 15 | $0.00 | |
| 80320 | 0% | 17 | $0.00 | |
| 80359 | 0% | 30 | $0.00 | |
| A6455 | Self-adherent bandage, elastic, non-knitted/non-woven, width greater than or equal to five inches, per yard | 0% | 14 | $0.00 |
| 96368 | 0% | 13 | $0.00 | |
| 90696 | 0% | 13 | $0.00 | |
| C1781 | Mesh (implantable) | 0% | 26 | $0.00 |
| 93270 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALLORE, GARY (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Mercy Health Partners | Shelby, MI | $8.01M |
| Mercy Health Partners | Muskegon, MI | $2.39M |
| Mercy Health Partners | Muskegon, MI | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.